<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763905</url>
  </required_header>
  <id_info>
    <org_study_id>20110116</org_study_id>
    <secondary_id>2012-001364-30</secondary_id>
    <nct_id>NCT01763905</nct_id>
  </id_info>
  <brief_title>Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2</brief_title>
  <acronym>GAUSS-2</acronym>
  <official_title>A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab
      every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from
      baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable
      to tolerate an effective dose of a statin (HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A)
      reductase inhibitors).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)</measure>
    <time_frame>Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lipoprotein (a) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12</measure>
    <time_frame>Baseline and Weeks 10 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">307</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe (Q2W)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe (QM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evolocumab QM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Evolocumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Evolocumab Q2W</arm_group_label>
    <arm_group_label>Evolocumab QM</arm_group_label>
    <other_name>AMG 145</other_name>
    <other_name>Repatha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Evolocumab</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Ezetimibe (Q2W)</arm_group_label>
    <arm_group_label>Ezetimibe (QM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Ezetimibe (Q2W)</arm_group_label>
    <arm_group_label>Ezetimibe (QM)</arm_group_label>
    <other_name>Zetia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to Ezetimibe</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Evolocumab Q2W</arm_group_label>
    <arm_group_label>Evolocumab QM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  Not on a statin or on a low dose statin with stable dose for at least 4 weeks

          -  History of intolerance to at least 2 statins

          -  Subject not at LDL-C goal

          -  Lipid lowering therapy has been stable prior to enrolment for at least 4 weeks.

          -  Fasting triglycerides ≤ 400 mg/dL

        Exclusion Criteria:

          -  New York Heart Association (NYHA) III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Type 1 diabetes, poorly controlled type 2 diabetes

          -  Uncontrolled hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2015</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lachine</city>
        <state>Quebec</state>
        <zip>H8S 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vénissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heppenheim</city>
        <zip>64646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midrand</city>
        <state>Gauteng</state>
        <zip>1685</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Observatory</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucía</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reus</city>
        <state>Cataluña</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reinach</city>
        <zip>4153</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Telford</city>
        <zip>TF1 6TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Bromwich</city>
        <zip>B71 4HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014 Mar;37(3):131-9. doi: 10.1002/clc.22248. Epub 2014 Jan 29.</citation>
    <PMID>24477778</PMID>
  </reference>
  <reference>
    <citation>Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocco M; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2541-2548. doi: 10.1016/j.jacc.2014.03.019. Epub 2014 Mar 30.</citation>
    <PMID>24694531</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <results_first_submitted>September 2, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2015</results_first_posted>
  <disposition_first_submitted>May 2, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 2, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 20, 2014</disposition_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Cholesterol, Treatment for high cholesterol, Lowering cholesterol, Lowering high cholesterol, Hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men and women ≥ 18 to ≤ 80 years of age who have tried at least 2 statins and were unable to tolerate any dose or increase in statin dose due to muscle-related side effects were eligible for this study.
The first participant was enrolled on 24 January 2013 and the last participant enrolled on 29 August 2013.</recruitment_details>
      <pre_assignment_details>Participants received subcutaneous placebo corresponding to the once monthly dose volume during a 6-week screening period. Those who completed the screening period and met final eligibility criteria were randomized 1:1:2:2 into 4 treatment groups. Randomization was stratified by low-density lipoprotein cholesterol (LDL-C) level and statin use.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe (Q2W)</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Ezetimibe (QM)</title>
          <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decision by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe (Q2W)</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Ezetimibe (QM)</title>
          <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="102"/>
            <count group_id="B5" value="307"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.7" spread="10.1"/>
                    <measurement group_id="B2" value="60.2" spread="8.7"/>
                    <measurement group_id="B3" value="60.5" spread="9.7"/>
                    <measurement group_id="B4" value="62.9" spread="10.2"/>
                    <measurement group_id="B5" value="61.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="98"/>
                    <measurement group_id="B5" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Low-density Lipoprotein Cholesterol (LDL-C) Level</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 180 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 180 mg/dL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Baseline Statin Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL-C Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194.7" spread="63.8"/>
                    <measurement group_id="B2" value="195.2" spread="51.8"/>
                    <measurement group_id="B3" value="192.0" spread="57.0"/>
                    <measurement group_id="B4" value="192.2" spread="61.2"/>
                    <measurement group_id="B5" value="193.1" spread="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231.4" spread="66.0"/>
                    <measurement group_id="B2" value="232.9" spread="57.0"/>
                    <measurement group_id="B3" value="227.9" spread="56.6"/>
                    <measurement group_id="B4" value="222.1" spread="63.2"/>
                    <measurement group_id="B5" value="227.4" spread="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140.0" spread="37.0"/>
                    <measurement group_id="B2" value="140.0" spread="31.1"/>
                    <measurement group_id="B3" value="140.2" spread="32.1"/>
                    <measurement group_id="B4" value="133.1" spread="32.2"/>
                    <measurement group_id="B5" value="137.8" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.989" spread="2.190"/>
                    <measurement group_id="B2" value="6.137" spread="1.787"/>
                    <measurement group_id="B3" value="5.912" spread="1.929"/>
                    <measurement group_id="B4" value="5.506" spread="1.925"/>
                    <measurement group_id="B5" value="5.827" spread="1.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apolipoprotein B/Apolipoprotein A1 Ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.943" spread="0.282"/>
                    <measurement group_id="B2" value="1.005" spread="0.294"/>
                    <measurement group_id="B3" value="0.980" spread="0.318"/>
                    <measurement group_id="B4" value="0.901" spread="0.283"/>
                    <measurement group_id="B5" value="0.952" spread="0.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipoprotein(a) Concentration</title>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.3" spread="101.0"/>
                    <measurement group_id="B2" value="76.6" spread="96.7"/>
                    <measurement group_id="B3" value="66.2" spread="72.5"/>
                    <measurement group_id="B4" value="70.9" spread="99.9"/>
                    <measurement group_id="B5" value="76.2" spread="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183.4" spread="79.8"/>
                    <measurement group_id="B2" value="187.0" spread="81.5"/>
                    <measurement group_id="B3" value="179.8" spread="80.0"/>
                    <measurement group_id="B4" value="149.3" spread="63.1"/>
                    <measurement group_id="B5" value="171.5" spread="76.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very Low-density Lipoprotein Cholesterol (VLDL-C) Concentration</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="16.0"/>
                    <measurement group_id="B2" value="37.1" spread="15.8"/>
                    <measurement group_id="B3" value="35.2" spread="14.5"/>
                    <measurement group_id="B4" value="29.9" spread="12.6"/>
                    <measurement group_id="B5" value="34.0" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-Density Lipoprotein Cholesterol (HDL-C)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="18.3"/>
                    <measurement group_id="B2" value="48.0" spread="11.0"/>
                    <measurement group_id="B3" value="51.1" spread="16.4"/>
                    <measurement group_id="B4" value="54.0" spread="16.0"/>
                    <measurement group_id="B5" value="51.8" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set (all randomized participants who received at least 1 dose of investigational product (subcutaneously or orally)) with available data (no imputation was performed).</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set (all randomized participants who received at least 1 dose of investigational product (subcutaneously or orally)) with available data (no imputation was performed).</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.08" spread="2.52"/>
                    <measurement group_id="O2" value="-15.05" spread="2.13"/>
                    <measurement group_id="O3" value="-56.14" spread="1.91"/>
                    <measurement group_id="O4" value="-52.60" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is no mean difference in the percent change from Baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis is that a mean difference does exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.87</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.73</ci_lower_limit>
            <ci_upper_limit>-32.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is no mean difference in the percent change from baseline at Week 12 in LDL-C between evolocumab and ezetimibe, and the alternative hypothesis is that a mean difference does exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-37.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.16</ci_lower_limit>
            <ci_upper_limit>-32.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.1" spread="5.1"/>
                    <measurement group_id="O2" value="-33.0" spread="4.5"/>
                    <measurement group_id="O3" value="-105.4" spread="3.9"/>
                    <measurement group_id="O4" value="-103.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-66.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-77.9</ci_lower_limit>
            <ci_upper_limit>-54.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-70.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-80.5</ci_lower_limit>
            <ci_upper_limit>-60.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.2" spread="5.4"/>
                    <measurement group_id="O2" value="-30.2" spread="4.7"/>
                    <measurement group_id="O3" value="-106.0" spread="4.1"/>
                    <measurement group_id="O4" value="-99.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-69.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-82.0</ci_lower_limit>
            <ci_upper_limit>-57.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-68.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-79.2</ci_lower_limit>
            <ci_upper_limit>-58.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)</title>
        <time_frame>Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.4" upper_limit="10.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O3" value="45.5" lower_limit="36.2" upper_limit="55.2"/>
                    <measurement group_id="O4" value="42.0" lower_limit="32.8" upper_limit="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>43.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.9</ci_lower_limit>
            <ci_upper_limit>53.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>42.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.3</ci_lower_limit>
            <ci_upper_limit>51.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With LDL-C &lt; 70 mg/dL (1.8 mmol/L) at Week 12</title>
          <population>Full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="0.4" upper_limit="10.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.9"/>
                    <measurement group_id="O3" value="50.0" lower_limit="40.3" upper_limit="59.7"/>
                    <measurement group_id="O4" value="37.5" lower_limit="28.5" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>48.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>35.0</ci_lower_limit>
            <ci_upper_limit>57.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel Haenszel test stratified by baseline LDL-C and statin use. For testing, non-achievement was imputed for participants with missing data.</method_desc>
            <param_type>Treatment Difference</param_type>
            <param_value>37.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25.5</ci_lower_limit>
            <ci_upper_limit>47.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.18" spread="2.15"/>
                    <measurement group_id="O2" value="-14.54" spread="1.86"/>
                    <measurement group_id="O3" value="-48.72" spread="1.64"/>
                    <measurement group_id="O4" value="-49.13" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-31.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.43</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.34</ci_lower_limit>
            <ci_upper_limit>-26.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.63</ci_lower_limit>
            <ci_upper_limit>-30.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Non-HDL-C at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.53" spread="2.30"/>
                    <measurement group_id="O2" value="-13.16" spread="1.93"/>
                    <measurement group_id="O3" value="-48.62" spread="1.74"/>
                    <measurement group_id="O4" value="-46.15" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.28</ci_lower_limit>
            <ci_upper_limit>-26.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.19</ci_lower_limit>
            <ci_upper_limit>-28.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full anlaysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12</title>
          <population>Full anlaysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.67" spread="2.15"/>
                    <measurement group_id="O2" value="-11.02" spread="2.21"/>
                    <measurement group_id="O3" value="-45.88" spread="1.68"/>
                    <measurement group_id="O4" value="-46.01" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.92</ci_lower_limit>
            <ci_upper_limit>-27.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.59</ci_lower_limit>
            <ci_upper_limit>-30.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.95" spread="2.32"/>
                    <measurement group_id="O2" value="-9.97" spread="2.34"/>
                    <measurement group_id="O3" value="-45.81" spread="1.79"/>
                    <measurement group_id="O4" value="-43.07" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-32.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.62</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.04</ci_lower_limit>
            <ci_upper_limit>-27.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-33.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.04</ci_lower_limit>
            <ci_upper_limit>-28.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.44" spread="2.14"/>
                    <measurement group_id="O2" value="-11.20" spread="2.16"/>
                    <measurement group_id="O3" value="-40.83" spread="1.65"/>
                    <measurement group_id="O4" value="-41.14" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.39</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.11</ci_lower_limit>
            <ci_upper_limit>-22.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-29.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.42</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.72</ci_lower_limit>
            <ci_upper_limit>-25.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.13" spread="2.30"/>
                    <measurement group_id="O2" value="-9.92" spread="2.34"/>
                    <measurement group_id="O3" value="-40.42" spread="1.75"/>
                    <measurement group_id="O4" value="-38.57" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-26.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.60</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.42</ci_lower_limit>
            <ci_upper_limit>-21.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-28.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.64</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.88</ci_lower_limit>
            <ci_upper_limit>-23.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.00" spread="2.27"/>
                    <measurement group_id="O2" value="-11.94" spread="2.56"/>
                    <measurement group_id="O3" value="-47.86" spread="1.77"/>
                    <measurement group_id="O4" value="-48.31" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.84</ci_lower_limit>
            <ci_upper_limit>-29.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.73</ci_lower_limit>
            <ci_upper_limit>-31.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.14" spread="2.47"/>
                    <measurement group_id="O2" value="-11.37" spread="2.71"/>
                    <measurement group_id="O3" value="-47.66" spread="1.90"/>
                    <measurement group_id="O4" value="-45.51" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.79</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.05</ci_lower_limit>
            <ci_upper_limit>-29.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-34.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.91</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.87</ci_lower_limit>
            <ci_upper_limit>-28.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="3.36"/>
                    <measurement group_id="O2" value="1.55" spread="4.01"/>
                    <measurement group_id="O3" value="-26.20" spread="2.64"/>
                    <measurement group_id="O4" value="-23.72" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-23.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.27</ci_lower_limit>
            <ci_upper_limit>-16.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-25.26</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.75</ci_lower_limit>
            <ci_upper_limit>-16.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lipoprotein (a) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lipoprotein (a) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="3.58"/>
                    <measurement group_id="O2" value="5.81" spread="5.10"/>
                    <measurement group_id="O3" value="-27.03" spread="2.78"/>
                    <measurement group_id="O4" value="-22.07" spread="3.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-25.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.26</ci_lower_limit>
            <ci_upper_limit>-17.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-27.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-39.21</ci_lower_limit>
            <ci_upper_limit>-16.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.74" spread="3.88"/>
                    <measurement group_id="O2" value="-0.32" spread="4.65"/>
                    <measurement group_id="O3" value="-6.32" spread="2.94"/>
                    <measurement group_id="O4" value="-6.73" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-2.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.45</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.38</ci_lower_limit>
            <ci_upper_limit>6.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-6.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.55</ci_lower_limit>
            <ci_upper_limit>3.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.47" spread="4.25"/>
                    <measurement group_id="O2" value="2.16" spread="5.52"/>
                    <measurement group_id="O3" value="-3.88" spread="3.18"/>
                    <measurement group_id="O4" value="-2.53" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>1.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.92</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.14</ci_lower_limit>
            <ci_upper_limit>11.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-4.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.04</ci_lower_limit>
            <ci_upper_limit>7.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="1.98"/>
                    <measurement group_id="O2" value="1.44" spread="2.03"/>
                    <measurement group_id="O3" value="5.48" spread="1.51"/>
                    <measurement group_id="O4" value="7.18" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>5.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>9.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>5.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>10.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77" spread="2.22"/>
                    <measurement group_id="O2" value="1.64" spread="2.22"/>
                    <measurement group_id="O3" value="5.34" spread="1.67"/>
                    <measurement group_id="O4" value="6.47" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.068</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>3.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>8.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>4.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>9.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.76" spread="3.80"/>
                    <measurement group_id="O2" value="-2.93" spread="4.41"/>
                    <measurement group_id="O3" value="-7.60" spread="2.89"/>
                    <measurement group_id="O4" value="-6.46" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-1.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.43</ci_lower_limit>
            <ci_upper_limit>6.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-3.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.85</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.12</ci_lower_limit>
            <ci_upper_limit>6.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12</title>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12</title>
          <population>Full analysis set</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.49" spread="4.05"/>
                    <measurement group_id="O2" value="-2.25" spread="5.11"/>
                    <measurement group_id="O3" value="-6.16" spread="3.08"/>
                    <measurement group_id="O4" value="-2.18" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-0.67</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.70</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.96</ci_lower_limit>
            <ci_upper_limit>8.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.33</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.24</ci_lower_limit>
            <ci_upper_limit>11.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
        <time_frame>Baseline and Weeks 10 and 12</time_frame>
        <population>Full analysis set with available data (no imputation was performed).</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe (Q2W)</title>
            <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe (QM)</title>
            <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Evolocumab Q2W</title>
            <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Evolocumab QM</title>
            <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12</title>
          <population>Full analysis set with available data (no imputation was performed).</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.21" spread="2.40"/>
                    <measurement group_id="O2" value="-16.62" spread="2.03"/>
                    <measurement group_id="O3" value="-56.11" spread="1.83"/>
                    <measurement group_id="O4" value="-55.31" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is no mean difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis is that a mean difference does exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-36.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.71</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.26</ci_lower_limit>
            <ci_upper_limit>-31.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there is no mean difference in the percent change from Baseline in the average value of LDL-C at Weeks 10 and 12 between evolocumab and ezetimibe, and the alternative hypothesis is that a mean difference does exist.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.</p_value_desc>
            <method>Repeated measures linear effects model</method>
            <method_desc>The model includes treatment group, baseline LDL-C level and statin use, scheduled visit, and the interaction of treatment with scheduled visit.</method_desc>
            <param_type>LS Mean Treatment Difference</param_type>
            <param_value>-38.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.06</ci_lower_limit>
            <ci_upper_limit>-34.22</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of blinded investigational product until the end of the study (up to 14 weeks).</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe (Q2W)</title>
          <description>Participants received placebo subcutaneous injection once every 2 weeks and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Ezetimibe (QM)</title>
          <description>Participants received placebo subcutaneous injection once a month and 10 mg ezetimibe orally once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Evolocumab Q2W</title>
          <description>Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and placebo tablets once a day for up to 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Evolocumab QM</title>
          <description>Participants received 420 mg evolocumab by subcutaneous injection once a month and placebo tablets once a day for up to 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cartilage graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Osteotomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

